An interventional study of Galleri Multi-Cancer Early Detection (MCED) in Genetic Predisposition to Cancer and Pancreatic Cystic Neoplasm, sponsored by University of Colorado, Denver. Not yet recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will study the feasibility of using multi-cancer early detection (MCED) testing in individuals at high risk for cancer development. We will look at participants to have germline mutations in cancer associated genes and participants who have pancreatic cysts. Participants will undergo testing and complete questionnaires to evaluating anxiety and adherence to standard screening after testing.
This study is evaluating the feasibility of using multi-cancer early detection (MCED) testing in individuals at high risk for cancer development. This will be done in two high risk populations. Participants with pathogenic or likely pathogenic germline mutations associated with moderate to high penetrance for cancer development (Cohort A) and those with high-risk pancreatic cysts (Cohort B).
Eligible participants will undergo testing and complete questionnaires to evaluating anxiety and adherence to standard screening after testing.
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in two high-risk cohorts (germline mutation carriers and individuals with high-risk pancreatic cysts) undergo Galleri multi-cancer early detection testing and follow-up assessments.
Diagnostic Test: Galleri Multi-Cancer Early Detection (MCED)
Patients who decide to enroll will undergo a blood draw to complete the Galleri MCED test and banking for future research, along with baseline sociodemographic, anxiety, cancer screening adherence, and cancer history questionnaires. After completing Galleri testing and receiving the results, patients will be directed to the cancer diagnostics clinic at AMC if they have a positive result. All patients will complete repeat anxiety, cancer history, and cancer screening adherence questionnaires at the 1-year and 2-year timepoints.
Feasibility of MCED testing in high risk populations
Feasibility will be established if 50% or more of participants offered MCED testing on this protocol accept, complete consent, and undergo MCED testing and if greater than or equal to 75% of participants with a positive MCED test complete evaluation in the Diagnostic Clinic.
Time frame: 2 years
Evaluate anxiety associate with MCED testing
Anxiety will be assessed by the Impact of Events Survey and GAD-7 Survey. Participants who complete the validated anxiety questionnaires at baseline and at least one follow-up time point will be included. Change scores will be analyzed using paired methods within participants and between MCED test result groups. Anxiety scores will be summarized descriptively at each assessment time point using means, standard deviations, medians, and interquartile ranges. Change from baseline will also be summarized descriptively for each time point.
Time frame: Anxiety will be assessed at Baseline, 1 year after MCED testing, and 2 years after MCED testing
Evaluate adherence to standard screening for individuals undergoing MCED testing
Participants who complete the validated cancer screening adherence questionnaire at baseline and at least one follow-up time point will be included. Change scores will be analyzed using paired methods within participants and between MCED test result groups. Adherence to standard of care cancer screening testing will be summarized descriptively at each assessment time point using means, standard deviations, medians, and interquartile ranges. Change from baseline will also be summarized descriptively for each time point.
Time frame: Cancer screening adherence will be assessed at Baseline, 1 year after MCED testing, and 2 years after MCED testing
Plan to share: Undecided — We need to consider what will and will not be shared given that this is a single institution trial
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Apr 2030, 39 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →